סרטיקן ® 0.25 מ"ג טבליות מסיסות

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

EVEROLIMUS 0.25 MG

Commercializzato da:

NOVARTIS PHARMA SERVICES AG

Codice ATC:

L04AA18

Forma farmaceutica:

TABLETS DISPERSIBLE

Via di somministrazione:

PER OS

Prodotto da:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Gruppo terapeutico:

EVEROLIMUS

Indicazioni terapeutiche:

Kidney and heart transplantationCertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids.Liver transplantationCertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.

Data dell'autorizzazione:

2010-02-01